Search hospitals > Oregon > Tualatin
Legacy Meridian Park Hospital
Claim this profileTualatin, Oregon 97062
Global Leader in Breast Cancer
Global Leader in Breast cancer
Conducts research for Lung Cancer
Conducts research for Ovarian Cancer
Conducts research for Glioblastoma
152 reported clinical trials
7 medical researchers
Summary
Legacy Meridian Park Hospital is a medical facility located in Tualatin, Oregon. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Ovarian Cancer, Glioblastoma and other specialties. Legacy Meridian Park Hospital is involved with conducting 152 clinical trials across 269 conditions. There are 7 research doctors associated with this hospital, such as Andrew Y. Kee, Mei Dong, Colleen C. McCormick, and Jacqueline Vuky, MD.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Andrew Y. KeeLegacy Good Samaritan Hospital and Medical Center3 years of reported clinical research
Studies Brain Tumor
Studies Lung Cancer
19 reported clinical trials
60 drugs studied
Mei DongLegacy Good Samaritan Hospital and Medical Center2 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
15 reported clinical trials
39 drugs studied
Colleen C. McCormickLegacy Good Samaritan Hospital and Medical Center5 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
13 reported clinical trials
44 drugs studied
Jacqueline Vuky, MDOregon Health and Science University8 years of reported clinical research
Studies Lung Cancer
Studies Cancer
10 reported clinical trials
24 drugs studied
Clinical Trials running at Legacy Meridian Park Hospital
Lung Cancer
Breast cancer
Breast Cancer
Ovarian Cancer
Uterine Cancer
Prostate Cancer
Glioblastoma
Laryngeal Cancer
Oropharyngeal Carcinoma
Prostate Adenocarcinoma
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting2 awards Phase 314 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Legacy Meridian Park Hospital?
Legacy Meridian Park Hospital is a medical facility located in Tualatin, Oregon. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Ovarian Cancer, Glioblastoma and other specialties. Legacy Meridian Park Hospital is involved with conducting 152 clinical trials across 269 conditions. There are 7 research doctors associated with this hospital, such as Andrew Y. Kee, Mei Dong, Colleen C. McCormick, and Jacqueline Vuky, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.